|
09 Feb 2021 |
Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration
|
|
09 Feb 2021 |
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
|
|
08 Feb 2021 |
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options
|
|
08 Feb 2021 |
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
|
|
06 Feb 2021 |
Spark Therapeutics Announces Preliminary Data from Phase 1/2 Clinical Trial of SPK-8016 in Hemophilia A at EAHAD 2021 Virtual Congress
|
|
06 Feb 2021 |
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
|
|
03 Feb 2021 |
Coya Therapeutics Completes Merger with Nicoya Health Inc. and Announces $10 Million Series A Financing to Advance Pipeline of Regulatory T cell Therapeutics Optimized for Neurodegeneration and Autoimmune Diseases
|
|
03 Feb 2021 |
Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)
|
|
03 Feb 2021 |
ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients
|
|
02 Feb 2021 |
BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy
|
|
02 Feb 2021 |
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute
|
|
01 Feb 2021 |
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease
|
|
01 Feb 2021 |
Janssen Announces CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
|
|
29 Jan 2021 |
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
|
|
29 Jan 2021 |
Focus on solid tumors - Discontinuation of MDG1021 development program
|
|
29 Jan 2021 |
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
|
|
28 Jan 2021 |
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
|
|
28 Jan 2021 |
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
|
|
28 Jan 2021 |
Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
|
|
22 Jan 2021 |
YESCARTA® Approved in Japan for Treatment of Patients with Relapsed/Refractory Large B-Cell Lymphomas
|
|
21 Jan 2021 |
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
|
|
21 Jan 2021 |
Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform
|
|
20 Jan 2021 |
T-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement for Novel HERV-E T Cell Receptor Therapy
|
|
20 Jan 2021 |
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
|
|
20 Jan 2021 |
Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration
|
